Multivariate Cox regression analysis of risk factors for time to reactivation at more than or equal to 250 and 1000 IU/mL before day 100 posttransplant
| ≥250 IU/mL . | . | . | . |
|---|---|---|---|
| Covariate . | Category . | HR (95% CI) . | P . |
| GVHD prevention method | MTX | 1 | |
| MMF | 1.50 (0.97-2.32) | .067 | |
| PTCy | 1.64 (1.03-2.61) | .039 | |
| Donor relationship | Sibling | 1 | |
| Unrelated | 1.44 (0.99-2.08) | .054 | |
| Donor CMV serostatus | − | 1 | |
| + | 0.94 (0.74-1.21) | .643 | |
| Conditioning regimen | Nonmyeloablative/RIC | 1 | |
| Myeloablative | 1.23 (0.80-1.89) | .349 | |
| Recipient age at transplant | As continuous | 1.00 (0.99-1.01) | .576 |
| Donor age at transplant | As continuous | 0.99 (0.98-1.00) | .063 |
| ≥250 IU/mL . | . | . | . |
|---|---|---|---|
| Covariate . | Category . | HR (95% CI) . | P . |
| GVHD prevention method | MTX | 1 | |
| MMF | 1.50 (0.97-2.32) | .067 | |
| PTCy | 1.64 (1.03-2.61) | .039 | |
| Donor relationship | Sibling | 1 | |
| Unrelated | 1.44 (0.99-2.08) | .054 | |
| Donor CMV serostatus | − | 1 | |
| + | 0.94 (0.74-1.21) | .643 | |
| Conditioning regimen | Nonmyeloablative/RIC | 1 | |
| Myeloablative | 1.23 (0.80-1.89) | .349 | |
| Recipient age at transplant | As continuous | 1.00 (0.99-1.01) | .576 |
| Donor age at transplant | As continuous | 0.99 (0.98-1.00) | .063 |
| ≥1000 IU/mL . | . | . | . |
|---|---|---|---|
| Covariate . | Category . | HR (95% CI) . | P . |
| GVHD prevention method | MTX | 1 | |
| MMF | 1.36 (0.68-2.72) | .391 | |
| PTCy | 1.22 (0.49-3.03) | .663 | |
| Donor relationship | Sibling | 1 | |
| Unrelated | 1.61 (0.84-3.09) | .15 | |
| Donor CMV serostatus | − | 1 | |
| + | 0.83 (0.55-1.26) | .379 | |
| Conditioning regimen | Nonmyeloablative/RIC | 1 | |
| Myeloablative | 0.76 (0.39-1.48) | .423 | |
| Recipient age at transplant | As continuous | 1.00 (0.98-1.02) | .974 |
| Donor age at transplant | As continuous | 0.99 (0.97-1.01) | .392 |
| ≥1000 IU/mL . | . | . | . |
|---|---|---|---|
| Covariate . | Category . | HR (95% CI) . | P . |
| GVHD prevention method | MTX | 1 | |
| MMF | 1.36 (0.68-2.72) | .391 | |
| PTCy | 1.22 (0.49-3.03) | .663 | |
| Donor relationship | Sibling | 1 | |
| Unrelated | 1.61 (0.84-3.09) | .15 | |
| Donor CMV serostatus | − | 1 | |
| + | 0.83 (0.55-1.26) | .379 | |
| Conditioning regimen | Nonmyeloablative/RIC | 1 | |
| Myeloablative | 0.76 (0.39-1.48) | .423 | |
| Recipient age at transplant | As continuous | 1.00 (0.98-1.02) | .974 |
| Donor age at transplant | As continuous | 0.99 (0.97-1.01) | .392 |